Xiansheng Pharmaceutical Group announced today that its self-developed monoclonal antibody targeting the interleukin-2 receptor beta chain long-acting antagonist sIM0725 has been approved by the China Drug Administration to conduct clinical trials in China and is intended to be used to treat autoimmune diseases.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.